BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 15547653)

  • 1. Losartan reduces left ventricular hypertrophy proportionally to blood pressure reduction in hypertensives, but does not affect diastolic cardiac function.
    Zakynthinos E; Pierutsakos Ch; Konstantinidis K; Zakynthinos S; Papadogiannis D
    Angiology; 2004; 55(6):669-78. PubMed ID: 15547653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
    Wachtell K; Bella JN; Rokkedal J; Palmieri V; Papademetriou V; Dahlöf B; Aalto T; Gerdts E; Devereux RB
    Circulation; 2002 Mar; 105(9):1071-6. PubMed ID: 11877357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
    Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Maisaidi M; Zanchetti A
    Blood Press; 2006; 15(2):107-15. PubMed ID: 16754274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Losartan controlled blood pressure and reduced left ventricular hypertrophy but did not alter arrhythmias in hypertensive men with preserved systolic function.
    Zakynthinos E; Pierrutsakos Ch; Daniil Z; Papadogiannis D
    Angiology; 2005; 56(4):439-49. PubMed ID: 16079926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of diastolic function after regression of left ventricular hypertrophy.
    Teniente-Valente R; Solorio S; Vargas-Salado E; Aguirre-Vázquez C; Hernández-González MA; Olvera-Lopez JA; Rodríguez-Mariscal L; Luna-Ruiz MA; Guillén Contreras JM; Murillo Ortiz BO
    Arch Cardiol Mex; 2008; 78(4):392-9. PubMed ID: 19205547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
    Fogari R; Mugellini A; Destro M; Corradi L; Lazzari P; Zoppi A; Preti P; Derosa G
    Diabet Med; 2012 Jan; 29(1):24-31. PubMed ID: 21781149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ambulatory 24-hour blood pressure monitoring: correlation between blood pressure variability and left ventricular hypertrophy in untreated hypertensive patients.
    Feola M; Boffano GM; Procopio M; Reynaud S; Allemano P; Rizzi G
    G Ital Cardiol; 1998 Jan; 28(1):38-44. PubMed ID: 9493044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of cilazapril therapy on diastolic filling and left ventricular hypertrophy in patients with arterial hypertension].
    De Simone R; Irace L; Perna B; Caruso C; Guida M; Iacono A
    Minerva Cardioangiol; 1993 May; 41(5):205-9. PubMed ID: 8355860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of hypotensive drugs on left ventricular mass and diastolic function].
    Spring A; Haczyński J; Jołda-Mydłowska B; Witkowska M
    Pol Arch Med Wewn; 1995 Jul; 94(1):47-58. PubMed ID: 8524699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.
    Bang CN; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Roman MJ; Køber L; Wachtell K; Devereux RB
    J Hypertens; 2013 Oct; 31(10):2060-8. PubMed ID: 23838656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Losartan improves regional left ventricular systolic and diastolic function in patients with hypertension: accurate evaluation using a newly developed color-coded tissue doppler imaging technique.
    Tanaka H; Oki T; Tabata T; Yamada H; Harada K; Kimura E; Oishi Y; Ishimoto T; Ito S
    J Card Fail; 2004 Oct; 10(5):412-20. PubMed ID: 15470652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study.
    Narayan P; Papademetriou V; Wachtell K; Gerdts E; Boman K; Nieminen MS; de Simone G; Dahlöf B; Fyhrquist F; Hoieggen A; Devereux RB
    Hypertension; 2006 May; 47(5):868-73. PubMed ID: 16567586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
    Devereux RB; Palmieri V; Liu JE; Wachtell K; Bella JN; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
    J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Regression of left ventricular hypertrophy and improvement of its diastolic function in patients with arterial hypertension under influence of antihypertensive therapy].
    Borzova NV; Gorbachenkov AA
    Kardiologiia; 2008; 48(6):44-50. PubMed ID: 18729836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
    J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
    Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study.
    Palmieri V; Okin PM; Bella JN; Wachtell K; Oikarinen L; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
    J Hypertens; 2006 Oct; 24(10):2079-84. PubMed ID: 16957569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
    Kucukler N; Kurt IH; Topaloglu C; Gurbuz S; Yalcin F
    J Cardiovasc Med (Hagerstown); 2012 Mar; 13(3):181-6. PubMed ID: 22306782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.